This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
AUA 2024
APCCC 2024
EAU 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2020
ASCO GU 2020
Prostate Cancer
Kidney Cancer
Bladder Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
ASCO GU 2020 Kidney Cancer
Viewing 41-57 of 57 articles
ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma: Radiotherapy
ASCO GU 2020: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pre-Treated Patients with Metastatic Renal Cell Carcinoma (NIVES)
ASCO GU 2020: Genetic Risk Assessment for Hereditary RCC: Report from the Consensus Panel Meeting
ASCO GU 2020: Best of the Journals – Renal Cell Carcinoma: Medical Oncology Perspective
ASCO GU 2020: Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
ASCO GU 2020: Toxicity Profiles and Side Effect Management of First-Line Treatment Options of Renal Cell Carcinoma
ASCO GU 2020: Overall Survival Results for Durvalumab and Savolitinib in Metastatic Papillary Renal Cancer
ASCO GU 2020: Prospective Observational Study on Pazopanib in Patients Treated for Advanced/Metastatic Renal Cell Carcinoma: APOLON Study
ASCO GU 2020: Overall Survival and Independent Review of Response in CheckMate 214 with 42-month Follow-up: First-line Nivolumab + Ipilimumab versus Sunitinib in Patients with Advanced Renal Cell Carcinoma
ASCO GU 2020: Combination of Dual Immune Checkpoint Inhibition with Stereotactic Radiation in Metastatic Renal Cell Carcinoma (RADVAX RCC)
ASCO GU 2020: NIVOREN GETUG-AFU 26 Translational Study: Association of PD-1, AXL, and PBRM-1 with Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab
ASCO GU 2020: Toxicity Profiles and Side Effect Management of First-Line Treatment Options in Renal Cell Carcinoma
ASCO GU 2020: A Phase I/II Trial of Sitravatinib Combined with Nivolumab in Patients with Advanced Clear Cell Renal Cell Cancer that Progressed on Prior VEGF-Targeted Therapy
ASCO GU 2020: A Phase I/II Study of the Oral HIF-2 α Inhibitor MK-6482 in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
ASCO GU 2020: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma: First Results of Phase II NIVES study.
ASCO GU 2020: Phase I/II Study of the Oral HIF-2 α Inhibitor MK-6482 in Patients with Advanced Clear Cell Renal Cell Carcinoma
ASCO GU 2020: Adding Radiation to Immunotherapy for mRCC: Improving Systemic Control Through Local Therapy
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free